CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1, cytochrome P450 family 2 subfamily D member 6, Cytochrome P450 2D6
外部ID
OMIM: 124030 HomoloGene: 133550 GeneCards: CYP2D6
遺伝子の位置 (ヒト)
染色体
22番染色体 (ヒト)[1]
バンド
データ無し
開始点
42,126,499 bp[1]
終点
42,130,906 bp[1]
RNA発現パターン
さらなる参照発現データ
遺伝子オントロジー
分子機能
• iron ion binding • metal ion binding • heme binding • oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen • drug binding • oxidoreductase activity • aromatase activity • oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen • steroid hydroxylase activity • monooxygenase activity
• steroid metabolic process • alkaloid metabolic process • coumarin metabolic process • 脂質代謝 • isoquinoline alkaloid metabolic process • alkaloid catabolic process • oxidative demethylation • drug catabolic process • heterocycle metabolic process • negative regulation of binding • drug metabolic process • monoterpenoid metabolic process • xenobiotic metabolic process • oxidation-reduction process • arachidonic acid metabolic process • negative regulation of cellular organofluorine metabolic process • long-chain fatty acid biosynthetic process • organic acid metabolic process • exogenous drug catabolic process
^ abcdefghijklmnopqrstuvwxyzaaabacadaeafagahaiajakalamanaoapaqarasatauavawaxayazbabbbcbdbebfbgbhbibjbkblbmbnbobpbqbrbsbtbubvbwbxbybzcacbcccdcecfcgFlockhart DA (2007年). “Drug Interactions: Cytochrome P450 Drug Interaction Table”. Indiana University School of Medicine. 2008年12月25日閲覧。
^ abcdefghijklmnopqrstuvwxyzaaabacadaeafFASS (drug formulary): Swedish environmental classification of pharmaceuticals Facts for prescribers (Fakta för förskrivare), retrieved July 2011
^ abPHARMACOGENETICS AND PHARMACOGENOMICS. J. Steven Leeder PharmD, PhD
Pediatric Clinics of North America - Volume 48, Issue 3 (June 2001). doi:10.1016/S0031-3955(05)70338-2.
^“Hydrocodone”. Drugbank. 2011年6月14日閲覧。
^Hoskins JM, Carey LA, McLeod HL (August 2009). “CYP2D6 and tamoxifen: DNA matters in breast cancer”. Nat. Rev. Cancer9 (8): 576–86. doi:10.1038/nrc2683. PMID 19629072.
^“Inhibition of CYP2D6 activity by bupropion”. J Clin Psychopharmacol25 (3): 226–9. (June 2005). PMID 15876900. http://Insights.ovid.com/pubmed?pmid=15876900.
^Zhang W, Ramamoorthy Y, Tyndale RF, Sellers EM (June 2003). “Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro”. Drug Metab. Dispos.31 (6): 768–72. doi:10.1124/dmd.31.6.768. PMID 12756210.
^ abcdeFASS, The Swedish official drug catalog > Kodein Recip Last reviewed 2008-04-08
^Cockshott ID (2004). “Bicalutamide: clinical pharmacokinetics and metabolism”. Clin Pharmacokinet43 (13): 855–78. doi:10.2165/00003088-200443130-00003. PMID 15509184.
^Foster BC, Sockovie ER, Vandenhoek S, Bellefeuille N, Drouin CE, Krantis A, Budzinski JW, Livesey J, and Arnason JT (2004). “In Vitro Activity of St. John's Wort Against Cytochrome P450 Isozymes and P-Glycoprotein”. Pharmaceutical Biology42 (2): 159–169. doi:10.1080/13880200490512034.
^He N, Zhang WQ, Shockley D, Edeki T (February 2002). “Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes”. Eur. J. Clin. Pharmacol.57 (12): 847–51. doi:10.1007/s00228-001-0399-0. PMID 11936702.
参考文献
加藤隆一ら 『薬物代謝学』～医療薬学・医薬品開発の基礎として～第3版,東京科学同人 ISBN 978-4-8079-0711-3
28
6
$begingroup$
Per the Font of Magic feature, sorcerer can use Flexible Casting to create 5th-level spell slots at level 7, even though they are not typically available until level 9. You can transform unexpended sorcery points into one spell slot as a bonus action on your turn. The Creating Spell Slots table shows the cost of creating a spell slot of [5th level is 7] If such a sorcerer levels up while still having this 5th-level spell slot, can they choose a 5th-level spell as the spell they gain upon levelling up? The Spellcasting feature states: Additionally, when you gain a level in this class, you can choose one of the sorcerer spells you know and replace it with another spell from the sorcerer spell list, which also must be of a level for which you have spell slots.
up vote
13
down vote
favorite
1
After the 2018 errata, the disintegrate spell description now reads: A creature targeted by this spell must make a Dexterity saving throw. On a failed save, the target takes 10d6 + 40 force damage. The target is disintegrated if this damage leaves it with 0 hit points. If you were to polymorph an enemy into a rat and then disintegrate it, would the enemy be disintegrated or would it just return to its original form? I know that for Druids, it’s not an instant kill anymore, but is this the case for polymorph as well?
dnd-5e spells polymorph errata
share | improve this question
edited 18 hours ago
3
3
$begingroup$
Recently, I saw a construction of topological invariant for $pi_3(U(n))$ with $ngeq 2$ : $$ N=frac{1}{24pi^2}int_{S^3} d^3x epsilon^{ijk} Tr[(U^{-1}partial_{x_i}U)(U^{-1}partial_{x_j}U)(U^{-1}partial_{x_k}U)] , $$ where $Uin U(n)$ depends on $boldsymbol{x}=(x_1,x_2,x_3)in S^3$ , $epsilon^{ijk}$ is the Levi-Civita symbol, $i,j,k=1,2,3$ , and the duplicated indexes are summed over. It is claimed that $N$ is an integer, but why? Update 02/02/2019 I think I got an argument for $n=2$ . In this case, $U=e^{i varphi} q$ with $qin SU(2)$ . Due to the trace and the Levi-Civita symbol in $N$ , $varphi$ does not contribute to $N$ . As $Tr[q^{dagger}partial_i q]=0$ and $(q^{dagger}partial_i q)^{dagger}=-q^{dagger}partial_i q$ , $q^{dagger}partial_i q$ in geneeral has the form $q^{dagger}partia
Mixing
